$428Million– No. of Holdings #13
Caligan Partners LP has about 96.6% of it's holdings in Healthcare sector.
Sector | % |
---|---|
Healthcare | 96.6 |
Others | 3.4 |
Caligan Partners LP has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
Category | % |
---|---|
SMALL-CAP | 51.3 |
MICRO-CAP | 25.9 |
MID-CAP | 19.4 |
UNALLOCATED | 3.4 |
About 60.5% of the stocks held by Caligan Partners LP either belong to S&P 500 or RUSSELL 2000 index.
Index | % |
---|---|
RUSSELL 2000 | 60.5 |
Others | 39.5 |
This heatmap illustrates the top 50 positions within the fund's portfolio.
Caligan Partners LP has 13 stocks in it's portfolio. About 96.2% of the portfolio is in top 10 stocks. LQDA proved to be the most loss making stock for the portfolio. ALIM was the most profitable stock for Caligan Partners LP last quarter.
Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
---|---|---|---|---|---|---|---|---|
AGIO | agios pharmaceuticals inc | 5.19 | 514,711 | 22,194,300 | added | 6.19 | ||
ALIM | alimera sciences inc | 21.87 | 16,835,200 | 93,603,500 | unchanged | 0.00 | ||
ANIK | anika therapeutics inc | 8.50 | 1,435,990 | 36,373,700 | unchanged | 0.00 | ||
BCRX | biocryst pharmaceuticals inc | 6.64 | 4,598,740 | 28,420,200 | added | 506 | ||
ENTA | enanta pharmaceuticals inc | 3.16 | 1,042,890 | 13,526,300 | added | 21.54 | ||
EOLS | evolus inc | 5.50 | 2,167,790 | 23,520,500 | added | 14.77 | ||
EXEL | exelixis inc | 8.01 | 1,525,730 | 34,283,200 | added | 38.61 | ||
IMAB | i mab | 1.32 | 3,374,790 | 5,635,900 | added | 346 | ||
LQDA | liquidia corporation | 29.05 | 10,360,900 | 124,331,000 | unchanged | 0.00 | ||
OTLK | outlook therapeutics inc | 0.86 | 500,000 | 3,690,000 | unchanged | 0.00 | ||
VRNA | verona pharma plc | 6.23 | 1,843,760 | 26,660,700 | added | 42.22 | ||
YMAB | y-mabs therapeutics inc | 1.64 | 582,078 | 7,031,500 | reduced | -0.89 | ||
mineralys therapeutics inc | 2.04 | 745,758 | 8,725,370 | new | ||||